Intra-Cellular Therapies ( NASDAQ:ITCI ) witnessed a sharp increase in its stock value, as it surged by 25% on Tuesday, following the success of its drug Caplyta in a depression treatment study. The drug has already been approved for the treatment of schizophrenia and depressive episodes in bipolar disorder patients, and the recent study has indicated its...
NASDAQ:ITCI orderly pullback to its 50 line MA after a strong move up.
Volume pattern looking strong with U/D north of 1.5
less than 2.8% risk to know if uptrend is resuming with inside day making for low risk entry.
ITCI is a biotech setting up for a potential breakout at the $60 level. The biotech sector is showing market-leading strength off the lows with many stocks in this group at or making new highs.
Relative strength ranks 97/100 and the company has seen triple-digit sales growth in each of the last four quarters.
Look for a breakout above the $60 mark on...
ITCI: Intra-Cellular Therapies Inc.
2022-04-25 07:00:00
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
*ITCI Made a New All Time High Yesterday
*7 Year Long Base Breakout
*As it has a bigger base so need to observe on weekly chart
*Very strong momentum
*Can be a decent swing play from here
With a huge upcoming catalyst - CAPLYTA PDUFA due December 17th, 2021, it will make or break this stock - with an approval from the FDA, I expect pt of around 57, with possibility to hit all-time high within a year from CAPLYTA launch. There is however always a possibility of CRL from the FDA, if that is the case, expect mid 20s - low 30s before recovering.
WATCHING $ITCI for ENTRY TARGET @ 37.23
Practicing to nail my entries even tighter… if target hits I will take a position.
Just because I'm watching doesn't mean I will actually take a position. I guess it just depends on what my portfolio is doing at the moment.
Intra-Cellular Therapies... That just sounds intense... I put this one on my watch list for next week.
Estmated Earnings 2-26..
No rising wedges in the yearly chart..
Short interest a bit over 10%..
There is also an inverse H&S pattern but target would put you at top of cup..
Mid Cup is 28.33. Support is often found under mid cup or handle low (HL)
Not a recommendation
$ITCI Reverse H&S - Holding $25 Support
Expecting a bounce off $25 near term. Targeting $30 gap-fill from January.
Bullish options activity recently - $5M bullish bet on $30 strike Aug calls yesterday
Note: Not investment advice.
Play is based on positive news or not in Mid 2020, if positive PH3, we will see explosive move again to as high as 40 - 60 but if negative, we can see ~15s --- It is good longer term stock since they do have a drug approved already and have plenty of cash on hand to hget the drug to the market - 240 sales reps and had $224 million in cash and equ. In my opinion,...
Hi Guys,
Some easy to spot moves using TrendSpotter on large and small caps. From $TSLA to $ITCI & $MBOT, TrendSpotter is there for you! I follow this setup all the time and stay out of the first few min to the entire first background until I get a reversal. You can use your own Risk Management system here but I like to sell half at about 50c to 75c and let the...
